Evidence map›Paper›PMID 28298360›Full record

ArticleAmerican journal of physiology. Renal physiology2017

Stimulation of fibroblast growth factor 23 by metabolic acidosis requires osteoblastic intracellular calcium signaling and prostaglandin synthesis.

Nancy S Krieger, David A Bushinsky

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Renal physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Effects of acid on bone.Kidney international · 2022
    Review
  4. Article
  5. Phosphate and fibroblast growth factor 23 in diabetes.Clinical science (London, England : 1979) · 2021
    Review
  6. Article
  7. Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.Cold Spring Harbor perspectives in medicine · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nancy S KriegerDivision of Nephrology, Department of Medicine, University of Rochester School of Medicine, Rochester, New York nancy_krieger@urmc.rochester.edu.
David A BushinskyDivision of Nephrology, Department of Medicine, University of Rochester School of Medicine, Rochester, New York.
University of Rochester · US

Funding

Hypercalciuria and Bone Quality in the Genetic Hypercalciuric Stone-Forming RatsR01DK075462 · NIDDK · UNIVERSITY OF ROCHESTER · PI BUSHINSKY, DAVID A · 2008 to 2019
$3.8M
NIDDK NIH HHS R01 DK075462
6 · The paper itself

Abstract

Serum fibroblast growth factor 23 (FGF23) increases progressively in chronic kidney disease (CKD) and is associated with increased mortality. FGF23 is synthesized in osteoblasts and osteocytes; however, the factors regulating its production are not clear. Patients with CKD have decreased renal acid excretion leading to metabolic acidosis (MET). During MET, acid is buffered by bone with release of mineral calcium (Ca) and phosphate (P). MET increases intracellular Ca signaling and cyclooxygenase 2 (COX2)-induced prostaglandin production in the osteoblast, leading to decreased bone formation and increased bone resorption. We found that MET directly stimulates FGF23 in mouse bone organ cultures and primary osteoblasts. We hypothesized that MET increases FGF23 through similar pathways that lead to bone resorption. Neonatal mouse calvariae were incubated in neutral (NTL, pH = 7.44, Pco

Indexed as

Bone ResorptionCalcium SignalingAcidosisAnimalsBoron CompoundsFibroblast Growth Factor-23Fibroblast Growth FactorsMiceNitrobenzenesOsteoblastsOsteogenesisPrimary Cell CultureProstaglandinsRenal Insufficiency, ChronicSulfonamides2-aminoethoxydiphenyl borateBoron CompoundsFgf23 protein, mouseFibroblast Growth Factor-23Fibroblast Growth FactorsN-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamideNitrobenzenesProstaglandinsSulfonamidesFGF23intracellular Cametabolic acidosisosteoblastprostaglandins

Identifiers

PMID28298360
PMCPMC5668590
OpenAlexW2603760871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.